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Agreeing on global research priorities for 
medication safety: an international prioritisation 
exercise
Objectives Medication errors continue to contribute substantially to global 
morbidity and mortality. In the context of the recent launch of the World 
Health Organization’s (WHO) Third Global Patient Safety Challenge: Med-
ication Without Harm, we sought to establish agreement on research priori-
ties for medication safety.
Methods We undertook a consensus prioritisation exercise using an ap-
proach developed by the Child Health and Nutrition Research Initiative. 
Based on a combination of productivity and citations, we identified lead-
ing researchers in patient and medication safety and invited them to partic-
ipate. We also extended the invitation to a further pool of experts from the 
WHO Global Patient Safety Network. All experts independently generated 
research ideas, which they then independently scored based on the criteria 
of: answerability, effectiveness, innovativeness, implementation, burden re-
duction and equity. An overall Research Priority Score and Average Expert 
Agreement were calculated for each research question.
Findings 131 experts submitted 333 research ideas, and 42 experts then 
scored the proposed research questions. The top prioritised research areas 
were: (1) deploying and scaling technology to enhance medication safety; 
(2) developing guidelines and standard operating procedures for high-risk 
patients, medications and contexts; (3) score-based approaches to predicting 
high-risk patients and situations; (4) interventions to increase patient medi-
cation literacy; (5) focused training courses for health professionals; and (6) 
universally applicable pictograms to avoid medication-related harm. Whilst 
there was a focus on promoting patient education and involvement across 
resource settings, priorities identified in high-resource settings centred on 
the optimisation of existing systems through technology. In low- and mid-
dle-resource settings, priorities focused on identifying systemic issues con-
tributing to high-risk situations.
Conclusions WHO now plans to work with global, regional and national 
research funding agencies to catalyse the investment needed to enable teams 
to pursue these research priorities in medication safety across high-, middle- 
and low-resource country settings.
Electronic supplementary material: 
The online version of this article contains supplementary material.
journal of
health
global
Medication errors are common and are responsible for considerable – potentially 
avoidable – morbidity and mortality [1]. They are also costly for patients, health 
systems and society; globally medication errors impose an estimated financial 
burden of US $42 billion per year, accounting for almost 1% of total expendi-
ture on health worldwide [2].
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Most studies of the frequency and nature of medication error have come from high-resource country set-
tings. These have found that around 2-3% of clinical encounters in primary care settings and 10% in-
volving hospital in-patients will result in errors [3-10]. Not all will be clinically important, but medica-
tion errors have been found to be the commonest resulting in harm [11]. Research in low-resource health 
care settings suggests a broadly comparable frequency of medication-related harm [6-12]. This body of 
work is challenging to interpret, because of the heterogeneity in the definitions used, patient populations 
studied and methodologies employed. Despite these challenges, the over-riding message from this body 
of evidence is very clear: medication errors affect patients of all ages, both sexes, occur globally across all 
health care settings, and, most importantly, they are largely preventable.
The World Health Organization (WHO) established two previous Global Patient Safety Challenges. Each 
Challenge sought to highlight a major patient safety problem impacting all countries and health systems. 
The first of these, Clean Care is Safer Care (2005) focused on reducing health care-associated infections 
and the second [13], Safe Surgery Saves Lives (2007), aimed to improve the safety of surgical processes 
[14]. Building on the success of these global initiatives, WHO launched the third WHO Global Patient 
Safety Challenge: Medication Without Harm in 2017 [15]. This seeks to facilitate a range of strategic ini-
tiatives with the aim of improving medication safety globally. Research is fundamental to these global, 
regional and national efforts. To inform these deliberations, we sought to define research priorities for 
medication safety using an inclusive, systematic and replicable process.
METHODS
Origins
We established a management team to identify global research priorities for medication safety. After re-
viewing available approaches for research prioritisation, we decided to employ the Child Health and Nu-
trition Research Initiative (CHNRI) method [16]. This research priority setting technique was introduced 
in 2007 and has now successfully been applied in over 100 different exercises, a number of which have 
also been led by WHO [17] (see Box 1). Revised guidelines for application of the method, based on the 
experience of its use, have recently been published [18-23]. This followed extensive deliberation on what 
was learnt from working with funders, researchers and other stakeholders over the last decade, as well 
as the development of a revised conceptual framework and validation of the key concepts that CHNRI 
relies on. In June 2017, we developed a protocol to guide the process for setting priorities in medication 
and patient safety research globally. A small management team (including the authors of this report) co-
ordinated the steps of the WHO priority setting exercise.
Expert input
We identified 598 experts in medication safety from across the world. We did so by searching the Web of 
Science’s Core Collection for the most productive authors in the preceding five-year period, or those who 
Box 1. The CHNRI method for setting research priorities
The CHNRI method uses the principle of crowdsourcing to score ideas against a pre-defined set of criteria. This 
enables funders and policymakers to view the strengths, the weaknesses, and relative ranking of each proposed 
research idea, based on submitted opinions of a larger number of experts. This method uses a systematic, trans-
parent, and democratic approach to priority setting. While it allows researchers to independently generate and 
score research questions, it also involves funders, policymakers, and other stakeholders at an early stage of the 
process, ensuring their ownership of the outcomes. The CHNRI method has thus far been implemented in about 
100 studies led by multilateral organisations (eg, WHO, United Nations International Children’s Emergency 
Fund (UNICEF)), national governments (eg, India, South Africa), and funders (eg, The Bill and Melinda Gates 
Foundation) to set research priorities in areas ranging from the reduction of global child mortality, dementia, 
or disability to the efficient execution of national health plans (eg, in China). The recognised advantages of this 
method include its systematic nature, transparency and replicability, clearly defined context and criteria, in-
volvement of the funders, stakeholders and policy makers, a structured way of obtaining information, informa-
tive and intuitive quantitative outputs, studying the level of agreement over each proposed research idea, and 
independent scoring of many experts, thus limiting the influence of individuals on the rest of the group [18-24].
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were lead authors of the top 1% most cited research articles. The key words used to identify the experts 
were “medication safety” and “patient safety”. After removing duplicate names, we invited the resulting 
457 researchers to participate. Each expert was invited to generate up to three research ideas and then 
systematically rank these using pre-agreed criteria (detailed below). We in addition approached 190 per-
sons who expressed interest in medication safety through the WHO’s Global Patient Safety Network. A 
total of 131 invitees agreed to participate and submitted their research ideas.
The management team then scrutinised the submitted ideas and ensured that the wording of each idea 
fitted the format for the scoring process. This led to a consolidated list of 333 unique research ideas, 
which were then thematically organised into 33 broader categories, each containing between three and 
30 research ideas.
The larger participating scorer group, comprising 42 experts, scrutinised the list of questions and agreed 
on the context and the criteria for scoring. The context was defined as “global.” This meant that some pro-
posed research ideas were scored differently because they were not feasible in specific settings. We asked 
the scorers to state whether the context they considered for the scoring process was for high-resource or 
low-resource settings. The resulting data were used for sub-analyses (see later).
Criteria
The timeframe within which the results were expected from proposed research was 5-10 years. Six in-
dependent criteria were agreed and used to discriminate between the many proposed research questions 
identified:
  (i)  Answerability: Is this research question likely to be answered using the proposed methods and 
approaches?
 (ii)  Effectiveness: Is this research question likely to lead to interventions that will effectively reduce 
the burden of medication-related harm?
(iii)  Innovativeness: Is this research question truly novel, making good use of overall technological 
and scientific progress?
(iv)  Implementation: Is this research question likely to lead to interventions or solutions that could 
be readily implemented?
 (v)  Burden reduction: Is this research question likely to lead to a significant reduction in medica-
tion-related harm?
(vi)  Equity: Is this research question likely to reduce inequity in the population?
All invited contributors were asked to score each submitted research question using these pre-defined 
criteria.
Scoring
Experts were offered four response options for scoring: 0 (unlikely to meet the criterion); 0.5 (not sure 
if it can meet the criterion); 1 (likely to meet the criterion); or left blank if the expert felt insufficiently 
informed to make a judgment. The scores for each criterion ranged from 0-100%, and the overall re-
search priority score (RPS) assigned to each research question was a simple mean of all six criteria-spe-
cific scores. Average expert agreement (AEA), defined as the level of agreement among scorers, was also 
calculated for each research question, as the frequency of the mode (ie, the most common score divided 
by the total number of scores).
RESULTS
We received scores for the 333 proposed research ideas from 42 experts (see Table S1 in Online Supple-
mentary Document). Most experts (n = 27) scored with a high-resource setting in mind. Five experts did 
not indicate which setting they had in mind while scoring. We present the scores from the overall pool 
of 42 experts in Table 1 and Table S2 in Online Supplementary Document, and the results by resource 
context in Table 2 and Table S3 in Online Supplementary Document (high-resource context), and in 
Table 3 and Table S4 in Online Supplementary Document (low-resource context). Table 4 shows the 
10 research questions with the most divergent scores based on the measure of AEA, which has a maxi-
mum theoretical range of 25%-100%. Table 5 shows the lowest ranked research priorities.
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Table 1. The top 20 research priorities among the 333 proposed research questions based on the scores from 42 experts in medica-
tion safety*
RANK 
ALL RESEARCH QUESTION
ANSWER-
ABLE
EFFEC-
TIVE
INNO-
VATIVE
IMPLE-
MENTABLE
BURDEN 
REDUCED
EQUI-
TABLE RPS AEA
1
To assess how the incidence of harm due to prescribing errors 
can be reduced by different interventions in low- and mid-
dle-income countries.
94 95 74 84 97 91 89.2 0.643
2
To assess the prevalence, main factors responsible and the ef-
fective interventions for preventing severe avoidable medica-
tion-related patient harm in resource-limited settings through 
pilot studies.
90 92 76 85 90 88 86.8 0.575
3 To identify affordable and effective methods of improving med-ication literacy among patients in resource limited settings 91 91 73 89 87 89 86.7 0.615
4 To develop a predictive algorithm to identify individuals who are at risk of serious medication-related harm. 88 91 90 79 94 76 86.2 0.742
5
To investigate the role of health communication strategies to 
support patients with limited language proficiency, health lit-
eracy and education in taking medications safely.
89 88 73 85 85 95 85.8 0.571
6
To assess the impact of increasing the amount of trained hu-
man resources to reduce medication errors in low- and mid-
dle-income countries
91 87 79 80 90 81 84.6 0.599
7
To develop and validate a complexity score (c-score) to iden-
tify the patients who are at risk of readmission in 30 d due to 
medication errors which could be used by pharmacists and 
physicians
91 85 79 90 88 72 84.3 0.631
8
To improve medication safety for in-patients, through the ap-
plication of ergonomics and human factors in the organization 
of the medications flow: order, distribution, stocking, prepara-
tion and administration.
92 86 76 86 89 75 83.9 0.575
9
To identify the most effective empowerment methods and tools 
for patients and their caregivers to speak up when they see the 
potential for medication-related harm, especially applicable to 
patients in LMICs, as often the most impacted individuals are 
poorer and less educated.
85 79 84 79 82 94 83.6 0.595
10
To develop and validate a complexity score (c-score) for pa-
tients in need for de-prescribing which would help the physi-
cians or pharmacists identify the high-risk patients who might 
develop drug-drug interactions.
91 84 80 86 84 75 83.3 0.563
11
To identify and develop globally applicable pictograms for se-
lected high-risk medications which would convey the critically 
important safety information
87 82 72 83 88 87 83.1 0.536
12
To conduct a study investigating the types of medication-related 
harm that occur in transitions between hospitals and primary 
care settings in LMIC.
97 86 63 83 89 80 82.8 0.571
13
To create patient knowledge-building tools for medication safe-
ty with critical thinking to ensure they are usable for people 
with low level of literacy, in a reliable format and addressing 
the role of internet as an information source.
88 83 80 81 78 86 82.6 0.623
14
To investigate how technologies could be appropriately imple-
mented and scaled in LMICs to better ensure that drugs are not 
spoiled, diverted, counterfeited, and that supply chain perfor-
mance is optimized to avoid stock outs and drug shortages.
83 90 70 83 84 82 82.0 0.452
15
To compare the benefits of pictorial information in medication 
instructions to written instructions alone, in improving med-
ication safety. To what extent, in what contexts and formats is 
pictorial information most beneficial?
88 78 80 80 76 83 81.0 0.500
16
To identify what national strategies and/or policies for medi-
cation safety across high-, middle-, and low-income countries 
exist. What gaps remain in identifying and implementing these 
prevention strategies/policies?
95 84 63 75 82 85 80.8 0.540
17 To evaluate the impact of medication reconciliation in prevent-ing medication errors in low-income countries. 94 85 63 73 85 83 80.6 0.563
18
To identify indicators of medication safety that have been uti-
lised in low-resource settings. What is known about their va-
lidity, reliability, and feasibility, and what potential indicators 
should be introduced?
93 80 69 83 78 80 80.6 0.508
19
To investigate how to ensure patient safety for patients utiliz-
ing oral home-based chemotherapy administration: maximising 
patient education and monitoring systems.
91 85 76 86 77 69 80.6 0.548
20 To identify the reliable easily measured indicators to assess medication safety both at a facility level and at national level 88 83 67 86 80 73 79.6 0.540
RPS – research priority score, AEA – average expert agreement
*Specific scores, ranging from 0-100, are presented for each of the 6 priority-setting criteria: answerability, effectiveness, innovativeness, implementabil-
ity, potential for burden reduction and equitability. Questions are ranked according to their overall research priority scores (RPS), which also has a max-
imum theoretical range of 0%-100%. Average expert agreement, which can theoretically range from 25%-100%, is also provided for each question.
Global research priorities for medication safety
www.jogh.org •  doi: 10.7189/jogh.09.010422 5 June 2019  •  Vol. 9 No. 1 •  010422
V
IE
W
PO
IN
TS
PA
PE
RS
The overall three highest-ranking research questions (with RPS 86.7-89.2) focused on:
•  Assessing how the incidence of harm due to prescribing errors can be reduced by different inter-
ventions in low-resource settings;
•  Assessing the prevalence, main factors responsible and effective interventions for preventing severe 
avoidable medication-related patient harm in low-resource settings through pilot studies;
•  Identifying affordable and effective methods of improving medication literacy among patients in 
resource-limited settings.
Figure 1 illustrates the key priorities for low- and high-resource settings.
Below, we consider the emerging themes, areas of overlap of priority areas, and discrepancies in more 
detail.
Recognised importance of low-resource settings
Our analysis shows that almost half (9 out of 20, 45%) of the top research priorities across experts related 
to identifying and addressing medication-related harm in low-resource settings (see Table 1). The priori-
tised questions included identifying existing incidence and prevalence of harm, training staff, identifying 
potential interventions (patient education/involvement, technology, effective medication reconciliation), 
and developing indicators. Three of the top 10 (30%) priorities identified by experts working in high-re-
source settings concerned tackling issues in low-resource settings (see Table 2).
Table 2. Top 10 research priorities among the 333 proposed research questions based on the scores from 27 experts in medication 
safety who were scoring mainly with a high-resource context in mind, and who represent a subset of the 42 scorers*
RANK RESEARCH QUESTION ANSWER-ABLE
EFFEC-
TIVE
INNO-
VATIVE
IMPLE-
MENTABLE
BURDEN 
REDUCED
EQUI-
TABLE RPS AEA
1
To compare the benefits of pictorial information in medication 
instructions to written instructions alone, in improving med-
ication safety. To what extent, in what contexts and formats is 
pictorial information most beneficial?
97 84 91 87 81 95 89.1 0.580
2
To identify and develop globally applicable pictograms for se-
lected high-risk medications which would convey the critically 
important safety information
93 88 80 89 94 90 89.0 0.599
3
To investigate how technologies could be appropriately imple-
mented and scaled in LMICs to better ensure that drugs are not 
spoiled, diverted, counterfeited, and that supply chain perfor-
mance is optimized to avoid stock outs and drug shortages.
91 100 77 88 90 87 88.7 0.500
4
To assess how the incidence of harm due to prescribing errors 
can be reduced by different interventions in low- and middle-in-
come countries.
95 97 71 75 100 87 87.4 0.568
5
To investigate the role of health communication strategies to 
support patients with limited language proficiency, health liter-
acy and education in taking medications safely.
90 86 71 85 83 100 85.9 0.599
6
To develop a predictive algorithm to identify individuals who 
are at risk of serious medication-related harm.
82 92 86 74 96 78 84.7 0.722
7
To identify affordable and effective methods of improving medi-
cation literacy among patients in resource limited settings
89 84 79 87 83 84 84.6 0.549
8
To identify and create recommendations for the most effective 
approach to decision support alerts in electronic prescribing 
systems, the optimum sensitivity and specificity and criteria 
which should be used to enable prescriber to receive alerts but 
not receive alert fatigue.
96 89 74 91 89 68 84.6 0.667
9
To create patient knowledge-building tools for medication safety 
with critical thinking to ensure they are usable for people with 
low level of literacy, in a reliable format and addressing the role 
of internet as an information source.
89 82 77 80 79 96 83.7 0.617
10
To develop and validate a complexity score (c-score) for patients 
in need for de-prescribing which would help the physicians or 
pharmacists identify the high-risk patients who might develop 
drug-drug interactions.
93 81 76 88 86 79 83.7 0.580
RPS – research priority score, AEA – average expert agreement
*Specific scores, ranging from 0-100, are presented for each of the 6 priority-setting criteria: answerability, effectiveness, innovativeness, implementabil-
ity, potential for burden reduction and equitability. Questions are ranked according to their overall research priority scores (RPS), which also has a max-
imum theoretical range of 0%-100%. Average expert agreement, which can theoretically range from 25%-100%, is also provided for each question.
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Exploring how to optimise existing systems through technology
Investigating how technology can be used to optimise existing efforts aimed at reducing medication-re-
lated harm was identified as a priority, particularly in high-resource settings (Table 2). The top 20 over-
all priorities comprised the development of predictive algorithms and risk scores (see Table 1), and in-
cluded human factors considerations, and information presentation. Of the top 10 priorities identified in 
high-resource settings (Table 2), four (40%) included technology (predictive algorithms and risk scores), 
technology in low-resource settings, and decision support systems. Pictorial information presentation fea-
tured in 20% of identified priorities, but it is unclear if these related to digital systems. Top priorities in 
low-resource settings did not include technology (Table 3).
Focus on organisational environments, learning and people
Patient education and involvement was mentioned in 25% (5 out of 20) top overall research priorities 
(Table 1). National strategies and policies were also mentioned, but only in 5% of overall research pri-
orities (Table 1).
30% of the highest ranking priorities in high-resource settings tackled patient education and involvement, 
but wider organisational and health system issues did not feature in the top 10 (Table 2).
Priorities in low-resource settings focused on wider questions around organisational environments in 
which issues surrounding medication safety are situated at a facility, system and national level (Table 3). 
Here, the top 10 research questions tackled exploring differences between settings with varying levels of 
income (30%), identifying systemic issues contributing to high-risk situations (20%), and promoting pa-
tient education and involvement (20%).
Overlap between lowest priority and most divergent perspectives
The research questions with the most divergent scores centred on research topics in specific settings eg, 
investigating health care-associated infections, antibiotics, generic medicines, over-the-counter (OTC) 
medicines (Table 4). Lowest-ranked research questions focused on single study designs in specific 
settings and medicines, but also included procedural issues such as identifying high-risk patients (see 
Table 5).
Figure 1. Key priorities for low- and high-resource settings.
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Table 3. Top 10 research priorities among the 333 proposed research questions based on the scores from 10 experts in medication 
safety who were scoring mainly with a low-resource context in mind, and who represent a subset of the 42 scorers*
RANK RESEARCH QUESTION ANSWER-ABLE
EFFEC-
TIVE
INNO-
VATIVE
IMPLE-
MENTABLE
BURDEN 
REDUCED
EQUI-
TABLE RPS AEA
1
To assess and identify the weak links in the medication safety 
process chain to consolidate the local systems and resolve the 
occurring difficulties and differences in practice.
88 100 94 94 94 100 94.8 0.733
2
To assess the prevalence, main factors responsible and the ef-
fective interventions for preventing severe avoidable medica-
tion-related patient harm in resource-limited settings through 
pilot studies.
94 94 100 89 94 94 94.3 0.750
3
To investigate the impact of addressing high alert medications 
on morbidity and mortality in two pilot sites, one in LMIC 
and one HIC.
100 100 88 94 89 89 93.3 0.800
4
To identify what national strategies and/or policies for medi-
cation safety across high-, middle-, and low-income countries 
exist. What gaps remain in identifying and implementing these 
prevention strategies/policies?
94 100 75 94 100 94 92.7 0.717
5
To identify the most effective empowerment methods and tools 
for patients and their caregivers to speak up when they see the 
potential for medication-related harm, especially applicable to 
patients in LMICs, as often the most impacted individuals are 
poorer and less educated.
89 90 90 95 94 95 92.2 0.833
6
What are the most frequent causes of severe, avoidable medi-
cation-related harm in high-, middle-, and low-income coun-
tries? If this is not known, what steps need to be taken to 
build and/or strengthen surveillance systems to identify med-
ication-related harm?
94 100 75 94 94 94 92.0 0.750
7
To identify and create new indicators and metrics for medi-
cation safety to measure better the impact of medication safe-
ty work.
93 93 93 93 93 86 91.7 0.583
8
To assess the reporting and learning of medication error sys-
tems at global and regional level and their impact on system 
change
94 89 81 94 89 100 91.2 0.750
9
To evaluate the prevalence of unnecessary medications and 
food supplements, drug-drug interactions and drug-disease 
interactions among patients who take multiple medications.
94 100 69 94 94 94 91.1 0.767
10
To investigate the correlations between patient education and 
engagement with adherence to medication, inappropriate pre-
scriptions and adverse drug events; and to identify which ed-
ucation tools are effective and sustainable.
94 95 80 100 95 80 90.7 0.850
RPS – research priority score, AEA – average expert agreement
*Specific scores, ranging from 0-100, are presented for each of the 6 priority-setting criteria: answerability, effectiveness, innovativeness, implementabil-
ity, potential for burden reduction and equitability. Questions are ranked according to their overall research priority scores (RPS), which also has a max-
imum theoretical range of 0%-100%. Average expert agreement, which can theoretically range from 25%-100%, is also provided for each question.
There was substantial overlap between six research priorities that were included in both the 10 research 
questions (60%) with the most divergent scores and the 20 lowest priority research questions (30%).
DISCUSSION
Our priority setting exercise has shown that medication safety is a truly global problem. Medicines are 
inadvertently killing and harming patients on a scale that is unacceptable. When viewed globally, and 
not from the perspective of some leading health care providers in high-resource countries, there has been 
relatively little improvement since the subject was first documented. This means that neither research, 
nor its translation into practice, has played a part in protecting patients. Taking a fundamental look at re-
search priorities in medication safety is a necessary step to create opportunities to transform this situation.
There was clear recognition by the experts who participated in our study of the need for research com-
missioners and funders to support ideas in scope to serve most of the world’s population, but also those 
that are innovative and with realistic prospects for implementation. At the opposite end of the priority 
spectrum were ideas either formulated too specifically or too focused on a specific context, or simply not 
clear enough. The significant overlap between the most controversial and the lowest priority areas sug-
gests that the notion of lowest priority is somewhat contested.
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Table 4. The 10 most controversial research questions among the 333 proposed research questions based on the measure of average 
expert agreement, which has a maximum theoretical range of 25%-100%*
RANK 
ALL RESEARCH QUESTION
ANSWER-
ABLE
EFFEC-
TIVE
INNO-
VATIVE
IMPLE-
MENTABLE
BURDEN
REDUCED
EQUI-
TABLE RPS AEA
321
To compare generic marking of every individual medication 
and dosage against existing medication in improving medica-
tion safety?
60 48 45 45 40 43 46.9 0.230
287
To conduct research into the development of expert systems en-
compassing a wide scope of patient information (including age, 
gender, genetic makeup, laboratory tests), to aid as a clinical de-
cision support.
54 56 54 54 61 54 55.2
0.
278
314
To perform an observational study to identify which laboratory 
tests can early diagnose a medication error.
48 46 58 44 46 54 49.5 0.282
242
To develop and validate models focused on aspects of hospital 
layout and health care worker/patient flow to reduce HAIs
73 54 55 66 64 52 60.6 0.282
317
To evaluate the efficacy of generic antibiotics compared to their 
original patented brand. Do they have the same impact on anti-
biotic-resistant bacteria in the digestive flora?
64 44 44 46 46 46 48.5 0.282
300
To determine factors that drive spread of HAIs and investigate 
new approaches that minimize the role of the health care envi-
ronment in the spread of germs
68 58 39 56 50 44 52.5 0.282
331
To conduct an exploratory study on the conditions and regula-
tions needed to adopt the prescription to OTC switch.
52 32 38 43 27 43 39.4 0.282
322
To conduct a study exploring implementation methods of drug 
classification systems in LMIC.
58 40 39 52 42 46 46.1 0.290
319
To assess the consequences to the individual's well-being and to 
their effectiveness when the workplace pursues complete elimi-
nation of avoidable harm.
50 50 52 46 48 39 47.6 0.290
210
To conduct a study investigating the impact of procurement 
based on clinical efficacy and safety, with the use of longitudinal 
data analytics thereby optimising benefits and minimising harm.
66 69 64 62 65 54 63.2 0.294
RPS – research priority score, AEA – average expert agreement
*The scores from 42 experts in medication safety contributed to this ranking. Overall ranks and scores (RPS) are also provided for each question.
The scorers also were of the view that research must encompass low-resource settings, where the bur-
den of medication-related harm is likely to be highest. Patient education and involvement were judged 
as priority areas across all care contexts. Priorities in high-resource settings focused on optimising exist-
ing systems through technology, whilst in low-resource settings priorities reflected the need for wider or-
ganisational changes.
The method we used to prioritise research needs is based on a systematic, well-documented process that 
is transparent and replicable. It is based on a collective opinion of experts. This eliminates the risk of 
individual scorers unduly influencing the overall score. We engaged many scorers (42 international ex-
perts), so there is a very high degree of confidence (>95%) that the ranking of priorities would not greatly 
change with a different group of scorers, unless major self-selection bias was present [23]. Differences in 
the contexts used to score are unlikely to have affected the scoring of most proposed research questions. 
They could however have had an important effect on proposed ideas that were considered not feasible 
in low-resource settings. This exercise also efficiently discriminated between a very large number of re-
search questions, with RPS spread over a very wide range (27.4-89.2, see Table S2 in Online Supple-
mentary Document).
In comparison to previously conducted CHNRI exercises, this work was characterised by a rather low re-
sponse rate at all stages of scoring. The initial response rate in a typical CHNRI exercise is around 60%, 
while the response rate at the second stage tends to be around 50% [16]. The scoring of this study was, 
compared to other CHNRI exercises, burdensome for scorers, so it is possible that this may have turned 
away many of the invited scorers. That said, simulations have shown that a sample size of 42 scorers 
should still result in stable and replicable scores and rankings [22,23]. To support this, research questions 
that were similar in nature were ranked very closely together on the final list, which is one of the useful 
indicators of robustness of the CHNRI process.
Another limitation relates to the search strategy and sample characteristics of experts. The search strategy 
for experts may not be representative as the first-author, with the exception of major trials, is seldom the 
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Table 5. The 20 lowest-ranked research questions among the 333 proposed research questions based on the scores from 42 experts 
in medication safety*
RANK ALL RESEARCH QUESTION ANSWER-ABLE
EFFEC-
TIVE
INNOVA-
TIVE
IMPLE-
MENTABLE
BURDEN 
REDUCED
EQUI-
TABLE RPS AEA
314
To perform an observational study to identify which 
laboratory tests can early diagnose a medication er-
ror.
48 46 58 44 46 54 49.5 0.282
315
To analyze and identify the root cause of multidrug 
resistance in the treatment process to create more 
effective interventions.
58 50 34 53 53 47 49.4 0.353
316
To conduct a longitudinal observational study of 
patient medication non-adherence on health out-
comes.
72 50 34 51 43 43 49.0 0.452
317
To evaluate the efficacy of generic antibiotics com-
pared to their original patented brand. Do they have 
the same impact on antibiotic-resistant bacteria in 
the digestive flora?
64 44 44 46 46 46 48.5 0.282
318
To compare the efficacy of generic medication to the 
original index drug and all other generic forms?
63 46 32 50 46 54 48.5 0.333
319
To assess the consequences to the individual's 
well-being and to their effectiveness when the 
workplace pursues complete elimination of avoid-
able harm.
50 50 52 46 48 39 47.6 0.290
320
To develop Shared Care Guidelines for selected med-
icines, to promote safe continuity of care in the com-
munity.
61 48 29 48 46 52 47.3 0.329
321
To compare generic marking of every individual 
medication and dosage against existing medication 
in improving medication safety?
60 48 45 45 40 43 46.9 0.230
322
To conduct a study exploring implementation meth-
ods of drug classification systems in LMIC.
58 40 39 52 42 46 46.1 0.290
323
To conduct a study investigating clinical situations 
that lie outside the guidelines, is there an increased 
incidence of unnecessary bridging with heparin or 
low molecular weight heparin?
60 47 40 55 40 34 45.9 0.353
324
To develop clinical guidelines for rarely used drugs 
and perform audits on use.
59 43 48 44 38 40 45.4 0.317
325
Assessing the benefits on patient safety and efficacy 
of marking expiration month and date on tablets.
62 39 41 53 38 40 45.4 0.349
326
To conduct an experimental study investigating the 
differences in the length of carriage of resistant bac-
teria, after exposure to a single course of antibiotics.
70 41 40 35 39 37 43.6 0.353
327
To develop digital thermometers for use with medi-
cine fridges and freezers.
66 42 23 59 30 40 43.2 0.413
328
To identify ways to ensure that the systemic prob-
lems (and failings) of medication safety amongst 
health care professionals will not conflict with the 
current trend of increasing patient knowledge and 
awareness.
45 38 47 43 43 40 42.8 0.341
329
To investigate the effect on patient safety if medica-
tion is infused through central vs peripheral veins.
58 42 26 52 44 27 41.4 0.433
330
To research into producing a medicines handbook 
that classifies medication by disease and patient 
group, that can be applied to different geographic 
country contexts.
44 36 43 40 36 45 40.6 0.369
331
To conduct an exploratory study on the conditions 
and regulations needed to adopt the prescription to 
OTC switch.
52 32 38 43 27 43 39.4 0.282
332
To create recommendations to accurately identify a 
patient which could be applied to different institu-
tional contexts.
50 42 27 48 38 25 38.2 0.329
333
To investigate the change in the status of the medi-
cation to create reliable processes.
29 31 24 28 28 26 27.4 0.325
RPS – research priority score, AEA – average expert agreement
*Specific scores, ranging from 0-100, are presented for each of the 6 priority-setting criteria: answerability, effectiveness, innovativeness, implementabil-
ity, potential for burden reduction and equitability. Questions are ranked according to their overall research priority scores (RPS), which also has a max-
imum theoretical range of 0%-100%. Average expert agreement, which can theoretically range from 25%-100%, is also provided for each question.
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most experienced author or “expert”. There was also clearly an overrepresentation of participants from 
high-resource settings (31 out of 42), which is likely to have influenced the results in favour of concerns 
important to those working in these settings. There was further a potential overrepresentation of phar-
macists/pharmacologists (18 out of 42), and medical doctors (11 out of 42).
Our findings provide detailed and actionable recommendations for policymakers and research funders 
to begin addressing the significant burden associated with medication-related harm internationally and 
in countries with different levels of resources (see Tables S2-S4 in Online Supplementary Document). 
Furthermore, the CHNRI process offers research funders and policymakers an opportunity to understand 
potential strengths and weaknesses of many research ideas when evaluated against pre-defined priori-
ty-setting criteria. This can lead to a multitude of follow-up actions, depending on individual preferences.
Across countries, research priorities reflected a need to identify incidence/prevalence of harm and asso-
ciated interventions (particularly in low-resource settings) as a necessary first step to improve medica-
tion safety. This is aligned with the current efforts of WHO to identify the prevalence of medication er-
rors in low-resource settings [15]. These settings have received limited attention in the literature [25]. It 
also reflects issues surrounding a lack of agreement on ways to define and measure medication-related 
harm [26,27].
Prioritised interventions tackled the alignment of informational requirements of the various stakehold-
ers involved in the medication management process (including the patient). Whilst patient involvement 
reflects a wider international drive towards the increasingly active role of patients in the management of 
their own health and illness to improve quality of care [28], patients may also be viewed as part of a wid-
er health information infrastructure surrounding medication-related information which is created and 
maintained by a wide variety of stakeholders [29].
This infrastructure may include both paper-based and electronic systems, depending on context. For in-
stance, technology-based approaches to optimising existing medication management through secondary 
uses of data are more immediately relevant to high-resource settings that already have basic technologi-
cal infrastructures in place [30]. Conversely, identified priorities in low-resource settings show that these 
countries need to focus on wider organisational changes to allow the emergence of basic informational 
infrastructures (technology-based or otherwise). This indicates that certain pre-requisites need to be in 
place before optimisation through technology can be considered [31].
CONCLUSIONS
Our method has identified and agreed research priorities for improving medication safety globally and 
by resource setting. WHO now plans to work with global, regional and national funding bodies to com-
mission work pursuing these research priorities and through doing so contribute to efforts to reduce the 
unacceptable burden of medication-related harm.
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